Allan C. Golston Sells 2,458 Shares of Stryker Co. (NYSE:SYK) Stock

Stryker Co. (NYSE:SYK) Director Allan C. Golston sold 2,458 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now directly owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. This trade represents a 14.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Stryker Stock Down 0.5 %

Shares of NYSE:SYK opened at $386.47 on Friday. The firm’s 50 day moving average price is $377.92 and its 200 day moving average price is $368.21. The stock has a market cap of $147.47 billion, a price-to-earnings ratio of 49.80, a price-to-earnings-growth ratio of 2.90 and a beta of 0.96. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the previous year, the company earned $3.46 EPS. As a group, equities research analysts predict that Stryker Co. will post 13.49 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a dividend of $0.84 per share. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.87%. Stryker’s payout ratio is currently 43.30%.

Wall Street Analyst Weigh In

SYK has been the subject of several research analyst reports. Canaccord Genuity Group increased their target price on shares of Stryker from $420.00 to $435.00 and gave the stock a “buy” rating in a research note on Wednesday, January 29th. Robert W. Baird increased their target price on shares of Stryker from $378.00 to $405.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Needham & Company LLC reaffirmed a “buy” rating and set a $442.00 target price on shares of Stryker in a research note on Wednesday, January 29th. JMP Securities reissued a “market perform” rating on shares of Stryker in a research report on Tuesday. Finally, Wells Fargo & Company increased their price target on shares of Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 29th. Five analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $420.68.

Institutional Trading of Stryker

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Kohmann Bosshard Financial Services LLC acquired a new stake in Stryker during the fourth quarter worth approximately $25,000. Dunhill Financial LLC raised its holdings in Stryker by 94.9% during the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 37 shares in the last quarter. Rakuten Securities Inc. grew its position in shares of Stryker by 618.2% during the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock worth $28,000 after acquiring an additional 68 shares during the last quarter. Centricity Wealth Management LLC purchased a new position in shares of Stryker during the fourth quarter worth approximately $30,000. Finally, BankPlus Trust Department purchased a new position in shares of Stryker during the fourth quarter worth approximately $33,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.